Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Jan 1;89(1):137-41.
doi: 10.1073/pnas.89.1.137.

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

Affiliations

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

D Teitelbaum et al. Proc Natl Acad Sci U S A. .

Abstract

Copolymer 1 (Cop 1) is a synthetic basic random copolymer of amino acids that has been shown to be effective in suppression of experimental allergic encephalomyelitis and has been proposed as a candidate drug for multiple sclerosis. Cop 1 is immunologically cross reactive with myelin basic protein (BP) and was shown to inhibit murine BP-specific T-cell lines of various H-2 restrictions. In the present study these findings were extended to include human T-cell lines. Cop 1 competitively inhibited the proliferative responses and interleukin 2 secretion of six BP-specific T-cell lines and 13 clones with several DR restrictions and epitope specificities. Conversely, BP inhibited--albeit to a lesser extent--the response of all the Cop 1-specific T-cell lines and clones, irrespective of their DR restrictions. Another random copolymer of tyrosine, glutamic acid, and alanine, denoted TGA, had no effect on these lines. Neither Cop 1 nor BP inhibited the response of lines and clones specific for purified protein derivative. Cop 1 and BP exerted their cross-inhibitory effects only in the presence of antigen-presenting cells. These results suggest that Cop 1 can compete with BP for the binding to human major histocompatibility complex molecules. In view of recent studies implicating BP reactivity in multiple sclerosis, these findings suggest a possible mechanism for the beneficial effect of Cop 1 in this disease.

PubMed Disclaimer

References

    1. Immunol Today. 1991 Aug;12(8):277-82 - PubMed
    1. Immunochemistry. 1976 Apr;13(4):333-7 - PubMed
    1. Immunol Today. 1990 Jan;11(1):21-4 - PubMed
    1. Eur J Immunol. 1973 May;3(5):273-9 - PubMed
    1. FEBS Lett. 1970 May 1;7(4):317-320 - PubMed

Publication types